Local Treatment of the Axilla in Early Breast Cancer: Concepts from the National Surgical Adjuvant Breast and Bowel Project B-04 to the Planned Intergroup Sentinel Mamma Trial
Toralf Reimer  Steffi Hartmann  Angrit Stachs  Bernd Gerber
Department of Obstetrics and Gynecology, University of Rostock, Germany

Keywords
Breast cancer · Axilla · Surgery · Radiotherapy · INSEMA

Summary
Local treatment of the axilla in clinically node-negative, early-stage breast cancer patients has been hotly debated after the release of the American College of Surgeons Oncology Group (ACOSOG) Z0011 findings. However, this review does not focus on the ‘Z0011-eligible’ patients alone, because this subgroup represents a minority of our patients undergoing breast-conserving surgery (BCS) and sentinel lymph node biopsy (SLNB). The following topics are discussed: axillary diagnostics, timing of axillary procedures in the neoadjuvant setting, long-term follow-up of SLNB trials, omission of axillary surgery in randomized trials, management of the involved axilla with low tumor volume, positive sentinel lymph nodes and BCS, involved sentinel lymph nodes and mastectomy, and axillary radiotherapy. Finally, the current innovative study concepts (i.e. Sentinel Node versus Observation after Axillary Ultrasound (SOUND) and Intergroup Sentinel Mamma (INSEMA)) including patients with axillary observation alone in clinically node-negative women are presented.

Introduction
At the moment, local treatment of the axilla in clinically node-negative, early-stage breast cancer patients is hotly debated after the release of the American College of Surgeons Oncology Group (ACOSOG) Z0011 [1, 2] and European Organisation for Research and Treatment of Cancer (EORTC) AMAROS trial data [3]. Highlight of this controversial discussion is the point-counterpoint review in the Cancer Research issue from December 15, 2013 [4–7]. Focus of these pro and contra statements is the question as to how radically the Z0011 findings can be applied to the routine clinical practice.

In a table, Morrow summarizes a series of prospective randomized trials, illustrating several key points relevant to axillary treatment [4]. In the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-04 study [8], where no irradiation and no systemic therapy was given, 1 axillary recurrence was observed for every 2.2 patients with disease left in the axilla. In contrast, in both the NSABP B-32 [9] and the International Breast Cancer Study Group (IBCSG) 23–01 [10] studies, this ratio decreased to 1 recurrence per 13 or 14 patients with residual nodal disease due to chemo- and radiotherapy use in more than 70% of the patients. Further reduction in regional recurrence (1 recurrence per 30 patients with pN+ status at axillary lymph node dissection (ALND)) was seen in the ACOSOG Z0011 trial [1, 2], where a greater proportion of the patients received postoperative adjuvant therapy.

In a figure of the counterpoint review, Sabel [6] presents a comprehensive algorithm for the management of cT1–T2 patients with invasive breast cancer, incorporating a multidisciplinary discussion. Of note, patients who require or desire mastectomy and sentinel lymph node biopsy (SLNB) are included in this flow chart. Late breaking American Society of Clinical Oncology (ASCO) abstracts for postoperative radiotherapy like AMAROS [3] and MA.20 presentations [11] were considered for the decision tree. These data may help to identify several ‘Z0011-ineligible’ patients who may still safely avoid ALND, such as mastectomy patients with involved sentinel lymph node (SLN) for whom postmastectomy radiotherapy (PMRT) is being considered (and an axillary field could be added). However, the most critical point of the described algorithm is the identification and management of ‘Z0011-eligible’ patients.
Data to support the multidisciplinary discussion regarding axillary treatment of clinically node-negative patients are summarized in this review. We do not focus on the ‘Z0011-eligible’ patients alone, because this subgroup represents a minority of our patients undergoing breast-conserving surgery (BCS) and SLNB in T1/T2 carcinomas. An analysis at the Memorial Sloan-Kettering Cancer Center (MSKCC) revealed that only 13.3% (287 of 2,157) of the patients were ‘Z0011 eligible’ between August 2010 and November 2012 [12]. A second important fact of this MSKCC paper is the low SLN-positive rate of 17.6% in the analyzed BCS cohort. This finding has been confirmed by another unicentric evaluation of 1,140 patients (T1/T2) with an SLN-positive rate of 13% [13]. All of these patients at the Mayo Clinic Rochester were clinically node-negative by preoperative axillary ultrasound (AUS) with or without fine-needle aspiration (FNA) biopsy. Recently, we have published our data from the University Hospital Rostock with an SLN-positive rate of 21.1% [14].

The reported SLN-positive rates of less than 22% in patients with BCS in the era of mammographic screening raise questions on the role of SLNB itself. Therefore, new trials were designed comparing SLNB versus observation when physical exam and AUS are negative in patients with BCS. The ongoing Sentinel Node versus Observation after Axillary Ultrasound (SOUND) trial and the planned Intergroup Sentinel Mamma (INSEMA) trial are discussed at the end of the review.

Axillary Diagnostics

Over the last 3 decades, many studies have shown the advantage of AUS to detect lymph node metastases in women with breast cancer. In a systematic review including 16 studies, the sensitivity ranged from 26.4% (95% confidence interval (CI): 15.3–40.3%) to 75.9% (95% CI: 56.4–89.7%) if morphological criteria were used. In these studies, the specificity varied between 88.4 and 98.1%. The combination of AUS and FNA led to a specificity improvement to nearly 100%, but the sensitivity could not be substantially increased (range between 30.6 and 62.9%) [15]. A recent meta-analysis from Houssami et al. [16] included 31 studies dealing with ultrasound-guided needle biopsy (UNB) in preoperative axillary staging. Data from 2,874 UNBs of 6,166 breast cancer patients were analyzed. The median prevalence of lymph node metastases was 47.2%. Modeled estimates for UNB showed a sensitivity of 79.6% (95% CI: 74.1–84.2%) and a specificity of 98.3% (95% CI: 97.2–99.0%). However, subgroup analysis revealed a higher diagnostic accuracy in patients with a higher underlying risk of lymph node metastases [16]. Moreover, uncertainty remains as to which ultrasound criteria including size, morphology, cortical thickness, and vascularity should be used to declare a lymph node as positive. Of these criteria, a longitudinal-transverse axis ratio (LT ratio) < 2, eccentric cortical thickening, and/or an absent fatty hilum as well as higher peripheral vascularity are reported as the most reliable criteria to predict lymph node metastases [17, 18]. The diagnostic performance of new imaging techniques like fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG PET/CT) and magnetic resonance imaging (MRI) is similar to that of AUS [19, 20]. With regard to the higher costs and possible side effects, PET/CT and MRI do not have a place in routine axillary staging. Finally, we have to take into account that exclusion of nodal metastatic infiltration is impossible with any imaging technique in about 25% of nodal metastases due to a size of ≤ 5 mm, which is below the reliability for detection [14].

Timing of Axillary Procedures in the Neoadjuvant Setting

Neoadjuvant systemic therapy is established for locally advanced breast cancer and increasingly used for early-stage disease as well [21]. The current recommendation is to perform SLNB in clinically and/or histologically/cytologically node-negative patients prior to systemic therapy, and axillary level I/II dissection in clinically and/or histologically/cytologically node-positive patients after neoadjuvant therapy [22, 23]. Nevertheless, the timing of axillary surgery in the neoadjuvant setting is controversial.

There is growing evidence that SLNB following neoadjuvant systemic therapy in patients without evident cancer in their axilla is acceptable and an additional surgical procedure could therefore be avoided in these women. To date, 4 meta-analyses that access the accuracy of SLNB after neoadjuvant chemotherapy have been published [24–27]. Although most of the included studies are limited by small size, retrospective design, and wide variation in results, the sentinel identification rates and false-negative rates determined were similar to those seen in patients undergoing SLNB before chemotherapy [28]. Anyway, because the lymphatic drainage from the breast could be impaired by primary systemic therapy and because the tumor regression pattern in the axilla is unknown, performing SLNB not before neoadjuvant therapy in clinically node-negative patients can be discussed with patients who wish to avoid 2 separate operations, but should not be recommended as routine procedure.

The second controversy deals with the potential to perform SLNB and to abandon level I/II dissection with its possible harms in patients with initial node-positive disease who are downstaged by neoadjuvant chemotherapy to cN0 and present with histologically negative SLN. Arm C of the prospective, multicentric SENTInel NeoAdjuvant (SENTINA) trial investigated the feasibility and accuracy of SLNB for this cohort of patients (n = 592). The sentinel detection rate was 80.1% and the false-negative rate was 14.2%. Although the detection rate and false-negative rate are inferior compared
to patients undergoing SLNB before neoadjuvant treatment, the detection rate was increased by a combined detection procedure (radiocolloid and blue dye) compared with the use of a radiocolloid alone (87.7% vs. 77.4%), and the false-negative rate decreased depending on the number of sentinel nodes removed (1 node 24.3%, 2 nodes 18.5%, 3 nodes 7.3%) [29]. These findings are supported by the ACOSOG Z1071 (Alliance) trial, a prospective multicenter study including women initially presenting with biopsy-proven cN1 breast cancer. For these patients undergoing both SLNB and level I/II dissection following chemotherapy, a false-negative rate of 12.6% was determined if 2 or more sentinel nodes were removed. The false-negative rate was significantly lower when dual mapping was used compared to a single mapping agent (10.8% vs. 20.3%) and when the number of removed sentinel nodes was ≥ 3 (2 nodes 21.1% vs. ≥ 3 nodes 9.1%) [30]. These studies demonstrate that when 3 or more sentinel nodes are harvested and dual sentinel detection procedures are used, the false-negative rate and the detection rate for initially clinically node-positive patients at SLNB after initial systemic treatment are comparable to those in initially node-negative patients. However, at the moment, we have no data regarding locoregional control and survival, and therefore further trials are needed to clarify which patients can be spared from ALND after initially lymph node-positive disease in the neoadjuvant setting.

**Long-Term Follow-Up of SLNB Trials**

The SLNB technique in breast cancer surgery was first described in 1994 with the aim to minimize morbidity associated with conventional ALND [31]. A current meta-analysis investigated the clinical effectiveness and safety of SLNB compared to ALND including only randomized controlled trials [2, 9, 32–37]. In the 8 included studies, a total of 8,560 patients were eligible for analysis (SLNB group n = 4,301; ALND group n = 4,259). The sensitivity of SLNB ranged from 93 to 97.1% and the false-negative rate from 5 to 22.9%. No significant differences between the groups with or without ALND could be found for DFS and OS [8, 43–45].

**Table 1. Prospective randomized clinical trials comparing ALND versus no axillary surgery**

<table>
<thead>
<tr>
<th>Author, study</th>
<th>Patients</th>
<th>N</th>
<th>Follow-up, years</th>
<th>Axillary recurrence</th>
<th>DFS</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fisher et al. (2002) [8], NSABP B-04</td>
<td>cN0, any age, radical ME vs. ME alone vs. ME + irradiation, no systemic therapy</td>
<td>1,079</td>
<td>25</td>
<td>18.6% in ME-alone arm</td>
<td>19% vs. 19% vs. 13%; p = 0.65</td>
<td>25% vs. 26% vs. 19%; p = 0.68</td>
</tr>
<tr>
<td>International Breast Cancer Study Group (2006) [43], IBCSG 10–93</td>
<td>pT1–2; cN0, ≥ 60 years, Tam</td>
<td>473</td>
<td>6.6</td>
<td>0.9% vs. 2.5%; n.s.</td>
<td>67% vs. 66%; p = 0.69</td>
<td>75% vs. 73%; p = 0.77</td>
</tr>
<tr>
<td>Martelli et al. (2012) [45]</td>
<td>cN0, pT1/T2 (≤ 2.5 cm), ≥ 65 years, Tam</td>
<td>219</td>
<td>15</td>
<td>0 vs. 3.6%</td>
<td>DDFS p = 0.95</td>
<td>p = 0.64</td>
</tr>
<tr>
<td>Agresti et al. (2013) [44], INT0198</td>
<td>cT1N0, 30–65 years, Tam, ≥ chemotherapy</td>
<td>565</td>
<td>10</td>
<td>0 vs. 9%</td>
<td>92.4% vs. 91.3%; p = 0.9</td>
<td>93.3% vs. 91.5%; p = 0.78</td>
</tr>
</tbody>
</table>

*42% of the patients with tumors > 2 cm.
ME = Mastectomy, Tam = tamoxifen, n.s. = non-significant, DDFS = distant disease-free survival.

As expected, the postoperative morbidity (lymphedema, numtness or paresthesia, impairment of arm mobility) was significantly higher in the ALND group [38]. The rate of lymphedema was reduced from 10–20% to 5–7%, arm numbness/pain from 31 to 11% [39]. Long-term follow-up showed that SLNB was associated with less morbidity than ALND [40].

Because of these conclusive data, axillary SLNB should be routine procedure in patients who have no palpable or ultrasound evidence of axillary metastases. Contraindications for SLNB are suspicious axillary lymph nodes and inflammatory breast cancer [23]. In spite of concerns regarding an impaired lymphatic drainage from the breast because of prior extensive breast surgery or previous axillary surgery, SLNB seems to be safe and feasible in these cases [41, 42]. In cases with doubtful sonographic findings, axillary FNA cytology or UNB is indicated. Patients with clinically, sonographically suspicious, or biopsy-proven positive axillary nodes are still candidates for ALND.

**Omission of Axillary Surgery: Published Randomized Trials**

Prior to establishing the efficacy and safety of SLNB, trials that compared axillary dissection versus no axillary surgery and versus axillary radiotherapy (ART) were conducted to avoid possible side effects of level I/II dissection.

Four prospective trials randomized breast cancer patients to standard axillary surgery versus no axillary surgery (table 1). These studies show a low rate of axillary recurrences, even in the arms without axillary surgery, although axillary lymph node involvement in the ALND group ranged from 23 to 40%. No significant differences between the groups with or without ALND could be found for DFS and OS [8, 43–45].

**Management of the Axilla in Early Breast Cancer**

Breast Care 2014;9:87–95

89
Notably, none of the mentioned randomized trials investigated ALND versus no axillary treatment including patients with suspicious axillary lymph nodes. Johansen et al. [46] reported no significant differences regarding DFS and OS after 50 years of follow-up for patients treated with radical mastectomy including ALND or simple mastectomy plus ART (n = 425). Veronesi et al. [47] randomized patients treated by BCS without palpable lymph nodes (n = 435) to ART versus no axillary treatment and found very low rates of axillary recurrence after a median follow-up of 63 months (0.5% vs. 1.5%, p = 0.3) and similar 5-year DFS rates for both groups (96.9% vs. 95.1%). A third available randomized trial compared patients with tumors of less than 3 cm and cN0 receiving ALND or ART (n = 658) [48]. Although axillary recurrences were more frequent in the ART group at 15 years of follow-up (1% vs. 3%, p = 0.04), DFS (64.3% vs. 65.5%) and OS (75.5% vs. 73.8%) were similar for both groups. ART in the setting of no prior axillary surgery has generally been associated with less morbidity. The incidence of morbidity after SLNB combined with ART has not been well characterized [49]. Because in patients without SLN metastases ART would result in an overtreatment, primary ART in patients without evidence of axillary metastases should not be conducted routinely [39].

Summarizing these data, avoiding axillary treatment in patients with clinically and sonographically insuspicious lymph nodes seems to be a safe option. Further studies are needed to define subgroups of patients who do not profit from axillary treatment and can be prevented from its possible side effects. In patients with suspicious axillary lymph nodes, ALND remains the standard treatment [22, 23].

**Management of the Involved Axilla with Low Tumor Volume**

Since the introduction of SLNB, pathological examination of lymph nodes has become more intensive, including routine use of a step-sectioning procedure, with or without immunohistochemical staining [50]. This resulted in an increased detection of small metastatic tumor deposits [51]. Whereas in the pre-SLN era metastatic deposits of 2 mm or smaller were classified as lymph node-positive micrometastatic disease, from 2002 up to now a distinction has been made between isolated tumor cells (ITCs), i.e. tumor cell clusters reaching not more than 0.2 mm in diameter, classified as nodal negative (pN0[i+]), and micrometastases, which are defined as metastatic deposits larger than 0.2 mm in diameter but not larger than 2 mm, classified as nodal positive (pN1mi) [52]. By the routine use of immunohistochemistry, an upstaging of 10% of the SLNB can be expected, but the clinical relevance of such occult metastases is doubtful. Non-sentinel node metastases are found in about 10% of patients with ITCs in the SLN and in 20–35% of patients with micrometastases in the SLN [53]. Therefore, the ASCO guideline published in 2005 for SLNB in early-stage breast cancer recommended completion ALND in the case of SLN micrometastases [50].

Today, the prognostic relevance of ITCs and micrometastases is negligible. The ACOSOG Z0010 trial included 5,210 patients with clinical T1 to T2N0M0 carcinomas treated with BCS and SLNB. Occult SLN metastases were present in 10.5% of the cases, but no differences in DFS and OS were seen [54]. The 10-year follow-up data of the NSABP B-32 trial (SLNB alone vs. SLN + ALND in SLN-negative patients) with prevalence of occult SLN metastases in 15.9% revealed a significant difference in DFS (p = 0.01) and a nearly significant difference in OS (p = 0.06). The locoregional recurrence was not significantly different between the occult and non-occult metastases groups (p = 0.52). However, the impact of occult metastatic nodal disease in this very large cohort (n = 5,611) with a DFS hazard ratio (HR) of 1.02 and an OS HR of 1.09 is clinically non-significant, and the routine use of immunohistochemistry for SLNB is not recommended by the NSABP B-32 investigators [55, 56].

Galamberti et al. [57] published a retrospective study including 377 patients with a single micrometastatic SLN who did not undergo completion ALND. After 5 years, the OS reached 97.3% and an incidence of axillary recurrence of 1.6% was found. Finally, these data were confirmed by the prospective randomized IBCSG 23–01 trial [10]. Including patients with 1 or more micrometastatic SLN with no extracapsular extension, no differences between the treatment arms were seen for survival outcomes comparing completion ALND versus observation. Therefore, completion ALND in case of SLN micrometastases is no longer recommended [58].

**Involved SLNs and BCS**

The presentation of the prospective, multicentric ACOSOG Z0011 trial at the ASCO meeting 2010 was a landmark for the discussion on surgical options in pN+ patients after SLNB. According to the protocol, nearly 900 patients with clinically T1/T2 cN0 cM0 breast cancer and BCS with metastatic involved SLN (detected by routine hematoxylin and eosin staining) were randomized to no further axillary dissection or completion ALND [1]. The targeted enrollment was 1,900 women, but the trial closed earlier due to lower than expected accrual and event rates. After a median follow-up of 6.3 years there were no significant differences between the SLNB alone and SLNB plus ALND arms concerning the 5-year local recurrence rate (1.6% vs. 3.1%), the 5-year DFS (83.9% vs. 82.2%), or the 5-year OS (92.5% vs. 91.8%). The local axillary recurrence rate was 0.9% for SLNB alone and 0.5% for SLNB + ALND [1, 2]. Because all patients were treated with opposing and tangential field irradiation, a local effect on the axilla could not be completely excluded, but it seems very unlikely in this dimension.
The lower part of the axilla is irradiated during breast-conserving therapy and receives a nearly therapeutic dose depending on the upper limit of the tangential fields to the breast or chest wall. A meta-analysis by van Wely et al. [59] showed that external-beam radiation therapy (EBRT) to the breast was associated with a lower axillary recurrence rate compared to patients who did not receive EBRT as part of their initial therapy after negative SLNB (0.4% vs. 1.2%; p < 0.001). These data indicate that a proportion of the radiation therapy will be given to the residual axillary nodes after SLNB. Although it may not be considered as therapeutic dose, the dose delivered to the region in which the SLNs are normally found could well influence the natural evolution of residual tumor cells [59]. The updated German S3 guideline (July 2012) summarizes these facts: In cases with standard EBRT to the breast (50 Gy), a dose of 20–40 Gy is expected for the ipsilateral axillary levels [60].

In March 2011, the German Working Group Gynecological Oncology (AGO) Breast Group adapted the current guidelines according to the ACOSOG Z0011 findings. Completion ALND is no longer recommended (only ‘+/–’ grade of recommendation) in patients with positive sentinel nodes and in case of: cT1/2, cN0, less than 3 sentinel nodes involved, BCS plus tangential breast irradiation, no alternative ART, and adequate systemic therapy [23]. Although these results seem somewhat definitive and provide strong support for the abandonment of ALND for ‘Z0011-eligible’ patients, there are several concerns regarding the design, accrual, and data collection (details in [6, 61]).

**Involved Sentinel Lymph Nodes and Mastectomy**

The ACOSOG Z0011 results have stimulated interest in the omission of completion ALND in other subgroups, such as total mastectomy patients. A previously discussed MSKCC paper focused on total mastectomy patients (n = 210) with positive SLNB who did not receive axillary-specific treatment [62, 63]. Characteristics and outcomes were compared to similar patients who underwent BCS (n = 325). At a median follow-up of 57.8 months, the 4-year locoregional failure rates were very low in both subgroups, without statistically significant differences between groups.

The MSKCC paper was not the first to suggest that low-risk patients who undergo total mastectomy may avoid completion ALND after positive SLNB. However, none of the cited studies was sufficiently powered to analyze mastectomy patients separately [64, 65]. Bilimoria et al. [66] analyzed a large cohort of the National Cancer Data Base (1998–2005) including women with clinically node-negative breast cancer who underwent SLNB and who had identified nodal metastases (median follow-up, 63 months). One asset of this paper is the differentiation between microscopic (0.2–2.0 mm) and macroscopic nodal disease (> 2.0 mm). Among 20,217 cases with SLNB alone, 3,757 patients were treated with mastectomy (18.6%). A proportion of these patients received adjuvant radiation therapy after mastectomy (n = 795). On univariate analysis, there was no significant difference in the axillary recurrence rate between SLNB alone versus SLNB with completion ALND in patients with macroscopic nodal metastases (1.0% vs. 1.2%) or microscopic nodal metastases (0.4% vs. 0.2%).

A prospective randomized trial for mastectomy patients with macrometastatic nodal disease after SLNB should be feasible after modification of the Z0011 design. As German specification, the issue of PMRT in cases with 1–2 involved SLNs could be incorporated in a randomization between SLNB alone versus PMRT with added axillary field. According to the St. Gallen 2013 consensus conference, the panel was nearly equally divided as to whether the Z0011 findings can also be applied to patients with mastectomy and 1–2 involved SLNs followed by PMRT, but was almost unanimous in the need for ALND if no PMRT was planned [67].

**Radiotherapy for Involved SLN**

Longtime follow-up data of clinical trials have shown that adjuvant radiotherapy after BCS decreases the risk of ipsilateral in-breast recurrence and distant recurrence, resulting in a significantly improved OS [68]. Radiotherapy after mastectomy in case of node-positive disease is well known to reduce local recurrences and improves OS by 6% [69]. PMRT trials almost included radiation of regional axillary, medial supraclavicular, and internal mammary lymph nodes.

The National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) MA.20 trial evaluated the addition of regional nodal irradiation (RNI; 45 Gy in 25 fractions to the internal mammary, supraclavicular, and high axillary lymph nodes) to whole-breast irradiation (WBI) following BCS. The median follow-up was 62 months and 1,832 women (90% node positive) were included. The results reported by Whelan et al. [11] demonstrated that additional RNI reduces the risk of isolated locoregional recurrence (94.5% vs. 96.8%) and improves DFS (84.0% vs. 89.7%). Additionally, there was a trend toward improvement in OS (90.7% vs. 92.3%). However, the MA.20 trial is not yet published and shows apparently contradictory findings to other studies. The 2.3% recurrence rate in the ALND (control) arm at 5 years is almost 5 times higher than that seen after ALND in the ACOSOG Z0011 (0.5%) or AMAROS (0.54%) trials, and equal to what was seen in the NSABP B-04 trial (2.5%) in the absence of systemic therapy, and raises questions about the contribution of the poor outcome in the control arm to the benefit of radiotherapy [7].

In the era of SLNB, the question arises whether ALND is necessary in case of positive SLNs. In the EORTC non-inferiority AMAROS trial, patients with early-stage breast cancer
and positive SLN were randomized between ALND and ART. With a median follow-up of 6.1 years, the axillary recurrence rate was 0.54% (4/744) in the ALND arm and 1.03% (7/681) in the ART arm. The axillary recurrence rate in case of a negative SLNB was 0.8%. The treatment arms did not show any significant differences regarding OS (93.3% ALND vs. 92.5% ART; p = 0.34) and DFS (86.9% ALND vs. 82.6% ART; p = 0.18). However, the rate of lymph edema was significantly lower in the ART subgroup [3].

According to the National Comprehensive Cancer Network (NCCN) guidelines there is no indication for ART besides macroscopic residual disease and the impossibility of surgical resection [22]. As a consequence from the AMAROS trial (17.4% with mastectomy) for ‘Z0011-ineligible’ patients with mastectomy and positive SLNB, irradiation of the axillary nodes is a valid option instead of completion ALND.

**Ongoing SOUND Trial**

The European Institute of Oncology (EIO) of Milan, Italy, designed the SOUND trial, which is a prospective randomized multicentric study representing a further step to answer the following key questions: Do we really need to look for an SLN? Do we really need the information obtained by identifying and examining the SLN?

The eligibility and exclusion criteria have been published in detail by Gentilini and Veronesi [70]. Briefly, patients with small breast cancer (T1) who are candidates for BCS and have a clinically node-negative axilla will undergo an AUS in order to rule out an evident or suspicious nodal involvement. Patients with either negative FNA cytology of a single doubtful lymph node or with negative AUS will be eligible for randomization into 2 groups: SLNB (+ ALND in all cases with SLN macrometastases) versus no axillary surgical staging.

The EIO investigators defined distant DFS (DDFS) as the primary endpoint of the SOUND trial, with the assumption that reliable results can be obtained in a shorter period of time compared to OS. Overall, 1,560 women (780 per arm) will be enrolled to decide whether the observation group is not worse than the SLNB group, given a margin Δ of non-inferiority of 2.5% (maximum tolerable 5-year DDFS = 94%) [70]. Officially, the first patient entered the SOUND trial in January 2012. So far (until December 2013), 375 patients have been randomized (O. Gentilini, personal communication).

**Planned INSEMA Trial**

The goal of the planned German/Austrian INSEMA study is to show that early-stage breast cancer patients with reduced extent of axillary surgery are not inferior regarding an invasive DFS (IDFS) outcome compared with the standard arm.

The inclusion criteria can be listed as follows:
- written informed consent prior to beginning BCS, including expected cooperation of the patients for follow-up
- histologically confirmed unilateral primary invasive carcinoma of the breast (core biopsy)
- age at diagnosis at least 35 years
- preoperative imaging techniques with estimated tumor size of ≤ 5 cm (iT1/iT2 irrespective of hormone sensitivity or HER2 status)
- clinically and sonographically tumor-free axilla prior to core biopsy (cN0/iN0)
- in cases with cN0 and iN1, a negative core biopsy or FNA cytology of the sonographically suspected lymph node is required before randomization
- no clinical evidence for distant metastasis (M0)
- planned BCS with postoperative standard external WBI

The exclusion criteria are:
- secondary malignancy, except curatively treated basalioma of the skin and carcinoma in situ of the cervix
- time since core biopsy > 3 months (optimal < 1 month)
- previous and already (neoadjuvantly) treated invasive breast carcinoma
- histologically non-invasive breast carcinoma
- clinically T3/T4 or imaging T3/T4 tumors
- very young patients aged < 35 years
- inadequate surgical treatment with histological incomplete resection (R1) of the invasive or intraductal tumor in the breast
- planned total mastectomy or secondary salvage mastectomy (primary care)
- planned intraoperative radiotherapy (e.g. intrabeam) or postoperative partial breast irradiation (e.g. multicathether technique) alone; both procedures are allowed as boost techniques
- male patients

In this trial, patients with breast cancer smaller or equal to 5 cm (T1/T2), a node-negative axilla (clinically and/or per imaging), planned BCS, and age ≥ 35 years can be recruited. Patients treated with mastectomy will be excluded due to the fact that (1) the majority of published prospective randomized trial data regarding omission of SLNB or completion ALND is limited to BCS and (2) the indication of PMRT is still linked to the number of involved lymph nodes.

Patients will be first randomized to either no axillary surgical intervention or axillary SLNB in a 1:4 allocation. Patients with SLNB and pN+ (sn) status will be secondly randomized to either SLNB alone or completion ALND in cases with less than 3 involved nodes (1 or 2 macrometastases). Patients with 3 or more macrometastatic SLNs should undergo completion ALND (fig. 1).

At 6,740, the total number of patients to be randomized into the trial will be quite high due to the unequal-sample size.
lyze potential axillary involvement during WBI, accurate and consistent contouring of the ipsilateral axilla (levels I–III) is essential for an evaluation of the INSEMA cases using published Radiation Therapy Oncology Group (RTOG) consensus definitions (Breast Cancer Atlas, www.rtog.org). Postoperative systemic treatment should be based on local multidisciplinary tumor board recommendations according to the current German AGO and S3 guidelines [23, 60].

The University of Rostock is the ‘sponsor’ of the INSEMA trial. After the final decision of the board of directors in December 2013, the study is funded by a German Cancer Aid (Deutsche Krebshilfe) grant. Launch of the study is planned for May/June 2014 in Germany.

Conclusions

Currently, axillary surgery for breast cancer is considered as staging procedure that does not seem to influence the breast cancer mortality, since the risk of developing metastasis depends mainly on the biological behavior of the primary (seed-and-soil model) [71]. Based on this, the postsurgical therapy should be considered on the basis of biologic tumor characteristics rather than nodal involvement.

Women with breast cancer have benefitted greatly from a series of carefully performed randomized controlled trials focusing on axillary surgery. Each successive trial showed that less surgery was better in that outcomes were the same and less surgical intervention resulted in fewer surgical complications. A fundamental point in ongoing or planned trials abandoning axillary surgery is the question of how carefully ‘clinically node-negative’ patients can be defined.

A high rate of locoregional control can be achieved with multimodality therapy, even without ALND. Despite increasing evidence disfavoring ALND, it remains part of the widely recognized guidelines for breast cancer. The modern approach in breast cancer care, which includes more detailed screening diagnostics, pathological evaluation, improved planning of surgical and radiation therapy, and more effective systemic treatment, emphasizes the need for ongoing re-evaluation of the ‘standard’ locoregional therapy.

Disclosure Statement

We declare that there are no conflicts of interest related to this review.

References


60 Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Langversion 3.0, Aktualisierung 2012. www.krebsgesellschaft.de /download/03_S3_Brustkrebs_Update_2012_Langversion.pdf.


